Report of the Crystal City Meeting to Maximize the Use of Organs Recovered from the Cadaver Donor

Rosengard, Bruce R.; Feng, Sandy; Alfrey, Edward J.; Zaroff, Jonathan G.; Emond, Jean C.; Henry, Mitchell L.; Garrity, Edward R.; Roberts, John P.; Wynn, James J.; Metzger, Robert A.; Freeman, Richard B.; Port, Friedrich K.; Merion, Robert M.; Love, Robert B.; Busuttil, Ronald W.; Delmonico, Francis L.

doi:10.1034/j.1600-6143.2002.20804.x

Cited by 330 publications

(228 citation statements)

References 0 publications

Supporting

Mentioning

207

Contrasting

Unclassified

Order By: Relevance

“…Another limitation is that donor kidneys in BENEFIT‐EXT were protocol defined by extended criteria that incorporated but were not limited to those consistent with the former United Network for Organ Sharing (UNOS) definition of ECD kidneys 48. When the protocol for BENEFIT‐EXT was being developed in 2003, these kidney subtypes were considered high risk under UNOS and other published criteria available at the time 8, 48; however, definitions of high‐risk kidneys have since evolved.…”

Section: Discussionmentioning

confidence: 99%

“…When the protocol for BENEFIT‐EXT was being developed in 2003, these kidney subtypes were considered high risk under UNOS and other published criteria available at the time 8, 48; however, definitions of high‐risk kidneys have since evolved. In 2013, the Kidney Donor Profile Index (KDPI) was introduced 49; therefore, the above findings are not necessarily predictive of outcomes that might be observed among recipients of donor kidneys with high (>85%) KDPI scores.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study

Dürrbach

Pestana

Florman

et al. 2016

American Journal of Transplantation

127

123

View full text Add to dashboard Cite

In the Belatacept Evaluation of Nephroprotection and Efficacy as First‐Line Immunosuppression Trial–Extended Criteria Donors (BENEFIT‐EXT), extended criteria donor kidney recipients were randomized to receive belatacept‐based (more intense [MI] or less intense [LI]) or cyclosporine‐based immunosuppression. In prior analyses, belatacept was associated with significantly better renal function compared with cyclosporine. In this prospective analysis of the intent‐to‐treat population, efficacy and safety were compared across regimens at 7 years after transplant. Overall, 128 of 184 belatacept MI–treated, 138 of 175 belatacept LI–treated and 108 of 184 cyclosporine‐treated patients contributed data to these analyses. Hazard ratios (HRs) comparing time to death or graft loss were 0.915 (95% confidence interval [CI] 0.625–1.339; p = 0.65) for belatacept MI versus cyclosporine and 0.927 (95% CI 0.634–1.356; p = 0.70) for belatacept LI versus cyclosporine. Mean estimated GFR (eGFR) plus or minus standard error at 7 years was 53.9 ± 1.9, 54.2 ± 1.9, and 35.3 ± 2.0 mL/min per 1.73 m2 for belatacept MI, belatacept LI and cyclosporine, respectively (p < 0.001 for overall treatment effect). HRs comparing freedom from death, graft loss or eGFR <20 mL/min per 1.73 m2 were 0.754 (95% CI 0.536–1.061; p = 0.10) for belatacept MI versus cyclosporine and 0.706 (95% CI 0.499–0.998; p = 0.05) for belatacept LI versus cyclosporine. Acute rejection rates and safety profiles of belatacept‐ and cyclosporine‐based treatment were similar. De novo donor‐specific antibody incidence was lower for belatacept (p ≤ 0.0001). Relative to cyclosporine, belatacept was associated with similar death and graft loss and improved renal function at 7 years after transplant and had a safety profile consistent with previous reports.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study

Dürrbach

Pestana

Florman

et al. 2016

American Journal of Transplantation

127

123

View full text Add to dashboard Cite

show abstract

“…In this issue of the American Journal of Transplantation, Miranda, Villardell and Grinyo (1) report their experience with cadaver organ donation in Spain, which is widely acclaimed for its success (2,3). Indeed, the 'Spanish Model' is a paradigm of performance that is unmatched by other countries throughout the world.…”

Section: Introductionmentioning

confidence: 99%

Assessing Organ Donation from the Dead Should Not Be Done by Reporting a Census of the Living

Luskin

Delmonico

2003

American Journal of Transplantation

Self Cite

View full text Add to dashboard Cite

“…If lung procurement is planned, colloid is the preferred agent. 40 Volume repletion should be guided by arterial waveform pulse pressure variation, central venous pressure, and urine output if diabetes insipidus is not an issue. Some centres target a mixed venous oxygen saturation • Hemodynamic instability…”

Section: Cardiacmentioning

confidence: 99%

Anesthetic considerations in organ procurement surgery: a narrative review

Anderson

Bekker

Vagefi

2015

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

Report of the Crystal City Meeting to Maximize the Use of Organs Recovered from the Cadaver Donor

Cited by 330 publications

References 0 publications

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study

Assessing Organ Donation from the Dead Should Not Be Done by Reporting a Census of the Living

Anesthetic considerations in organ procurement surgery: a narrative review

Contact Info

Product

Resources

About